B Cell Activating Factor, Renal Allograft Antibody-Mediated Rejection, and Long-Term Outcome.

about

B Cell Activating Factor, Renal Allograft Antibody-Mediated Rejection, and Long-Term Outcome.

Item

http://www.wikidata.org/entity/Q55449985

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh

2018年學術文章

@zh-hant

name

B Cell Activating Factor, Rena ...... ection, and Long-Term Outcome.

@en

B Cell Activating Factor, Rena ...... ection, and Long-Term Outcome.

@nl

type

Item

label

B Cell Activating Factor, Rena ...... ection, and Long-Term Outcome.

@en

B Cell Activating Factor, Rena ...... ection, and Long-Term Outcome.

@nl

prefLabel

B Cell Activating Factor, Rena ...... ection, and Long-Term Outcome.

@en

B Cell Activating Factor, Rena ...... ection, and Long-Term Outcome.

@nl

P1476

B Cell Activating Factor, Rena ...... jection, and Long-Term Outcome

@en

P2093

Renfang Xu

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution 4.0 International

P2860

Adipocytes as immune cells: differential expression of TWEAK, BAFF, and APRIL and their receptors (Fn14, BAFF-R, TACI, and BCMA) at different stages of normal and pathological adipose tissue development

Exploring BAFF: its expression, receptors and contribution to the immunopathogenesis of Sjögren's syndrome

BAFF and BAFF-R levels are associated with risk of long-term kidney graft dysfunction and development of donor-specific antibodies

Elevated pretransplantation soluble BAFF is associated with an increased risk of acute antibody-mediated rejection

Neutralizing BAFF/APRIL with atacicept prevents early DSA formation and AMR development in T cell depletion induced nonhuman primate AMR model.

B cell-activating factor of the tumor necrosis factor family (BAFF) is expressed under stimulation by interferon in salivary gland epithelial cells in primary Sjögren's syndrome

Microvascular inflammation in early protocol biopsies of renal allografts in cases of chronic active antibody-mediated rejection.

Clinical Significance of Pre- and Post-Transplant BAFF Levels in Kidney Transplant Recipients.

Antibody-Mediated Rejection Due to Preexisting versus De Novo Donor-Specific Antibodies in Kidney Allograft Recipients.

IgG Donor-Specific Anti-Human HLA Antibody Subclasses and Kidney Allograft Antibody-Mediated Injury.

P304

5251801

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1155/2018/5251801

http://www.w3.org/2001/XMLSchema#string

P478

2018

http://www.w3.org/2001/XMLSchema#string

P50

Haiyan Xu

Xiaozhou He

P577

2018-06-06T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29977928

http://www.w3.org/2001/XMLSchema#string

P921

peptide

anatomical region

membrane proteins

P932

6011068

http://www.w3.org/2001/XMLSchema#string